Literature DB >> 2509392

Experience in the treatment of localized carcinoma of the prostate by definitive external irradiation.

A Kuten1, S Nitetzky, M Tatcher, Y Cohen, E Robinson.   

Abstract

One hundred and sixteen patients with stages A2, B, and C histologically proven adenocarcinoma of the prostate were treated by definitive radiation. They received first whole pelvic irradiation, 46 Gy in 23 treatments, followed by a prostatic "boost" of 20 Gy in 10 fractions. Five-year survival rates varied between 39 and 84%. Prophylactic hormonal manipulation and transurethral resection of the prostate (TURP) did not influence survival figures. Complications of radiotherapy were in an acceptable range. It is concluded that external beam irradiation is an effective, simple, and usually well-tolerated treatment modality for localized carcinoma of the prostate. Stage and degree of differentiation and response of the primary tumour to radiation are predictors of patient outcome. There is no advantage in prophylactic hormonal manipulation, and TURP does not influence survival according to our experience.

Entities:  

Mesh:

Year:  1989        PMID: 2509392     DOI: 10.1007/bf02559744

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  14 in total

1.  Behavioral patterns of prostate adenocarcinoma following an 125I implant and pelvic node dissection.

Authors:  B S Hilaris; W F Whitmore; M Batata; W Barzell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Jul-Aug       Impact factor: 7.038

2.  Current conflicts in the management of prostatic cancer.

Authors:  M A Bagshaw
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-10       Impact factor: 7.038

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

4.  Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience.

Authors:  G R Ray; J R Cassady; M A Bagshaw
Journal:  Radiology       Date:  1973-02       Impact factor: 11.105

5.  The adverse influence of prior transurethral resection on prognosis in carcinoma of prostate treated by radiation therapy.

Authors:  D G McGowan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-09       Impact factor: 7.038

6.  Radical external radiotherapy for prostatic carcinoma.

Authors:  D D Beiler; D J Wright; G N Reddy
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-07       Impact factor: 7.038

7.  Local control and reduced complications in split course irradiation of prostatic cancer.

Authors:  J L Pino y Torres; D J Lee; S A Leibel; M D Wharam; B B Cantrell; D S Bross; S E Order
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-01       Impact factor: 7.038

8.  Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis.

Authors:  C A Perez; B J Walz; F R Zivnuska; M Pilepich; K Prasad; W Bauer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-05       Impact factor: 7.038

9.  Carcinoma of the prostate: treatment with external radiotherapy.

Authors:  L Harisiadis; R J Veenema; J J Senyszyn; P J Puchner; P Tretter; N A Romas; C H Chang; J K Lattimer; M Tannenbaum
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

10.  The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate.

Authors:  J D Cox; T J Stoffel
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

View more
  2 in total

1.  The incidence of rectal bleeding following three-dimensional conformal radiotherapy of prostatic cancer.

Authors:  C Kurtman
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Update of experience in the treatment of localized carcinoma of the prostate by definitive external irradiation.

Authors:  A Kuten; B Nitetzky; Y Cohen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.